Mylan Receives Approval for Biosimilar in India; Reaches Settlement with Teva on Copaxone - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mylan Receives Approval for Biosimilar in India; Reaches Settlement with Teva on Copaxone


The generic-drug/specialty pharmaceutical company Mylan and the Indian biopharmaceutical company Biocon have received approval for a biosimilar version of trastuzumab in India. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name Hertraz.

Trastuzumab is one of five biologic products Mylan is developing in partnership with Biocon. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the United States, Canada, Japan, Australia, New Zealand, and countries in the European Union and European Free Trade Association and co-exclusive commercialization rights with Biocon for the product in India. Mylan expects to launch trastuzumab in India early in 2014.

In other news, Mylan reports that it and Teva Pharmaceutical Industries have agreed to settle and dismiss pending patent litigation involving Teva's e multiple-sclerosis drug Copaxone (glatiramer acetate) in the United Kingdom, the Netherlands, and France relating to noninfringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential.

Source: Mylan and Teva Pharmaceutical Industries

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here